Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
暂无分享，去创建一个
A. Go | Jingrong Yang | J. Gurwitz | R. Platt | J. Hsu | Kimberly Lane
[1] G. Fonarow,et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2007, American heart journal.
[2] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[3] A. Go,et al. Gender and risk of adverse outcomes in heart failure. , 2004, The American journal of cardiology.
[4] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[5] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[6] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[7] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[8] J. Selby,et al. Excess Costs of Medical Care for Patients With Diabetes in a Managed Care Population , 1997, Diabetes Care.